Advertisement

Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 12

JAK Inhibitor Selectivity and Dose-Related Toxicity

Published on: 
, , , ,

Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.

Video content above is prompted by the following:

Mechanism of action also differs in the Janus kinase (JAK) inhibitor class. Tofacitinib inhibits JAK1/JAK2/JAK3, baricitinib inhibits JAK1/JAK2, and upadacitinib inhibits JAK1. Can you describe how more specific selectivity of JAK inhibition influences dose-related toxicity?

Advertisement
Advertisement